Evidence of meeting #19 for Health in the 43rd Parliament, 2nd Session. (The original version is on Parliament’s site, as are the minutes.) The winning word was vaccines.

A recording is available from Parliament.

On the agenda

MPs speaking

Also speaking

Caroline Quach-Thanh  Chair and Professor, Université de Montréal, National Advisory Committee on Immunization
Cindy Evans  Acting Vice-President, Emergency Management, Public Health Agency of Canada
Guillaume Poliquin  Acting Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada
Roman Szumski  Senior Vice-President, COVID-19 Vaccine and Therapeutics Acquisitions, Public Health Agency of Canada
Bersabel Ephrem  Director General, Centre for Communicable Disease and Infection Control, Public Health Agency of Canada
Kimberly Elmslie  Senior Vice-President, Immunization Program, Public Health Agency of Canada
Stephen Bent  Director General, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada

3:20 p.m.

Acting Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada

Dr. Guillaume Poliquin

Mr. Chair, the modelling that was presented today is looking at projections for the number of cases that could be expected, based on a number of different conditions.

3:20 p.m.

Conservative

Michelle Rempel Conservative Calgary Nose Hill, AB

Could you please table with committee the conditions you had made assumptions on with regard to your modelling today?

3:20 p.m.

Acting Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada

3:20 p.m.

Conservative

Michelle Rempel Conservative Calgary Nose Hill, AB

By next week?

3:20 p.m.

Acting Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada

3:20 p.m.

Conservative

Michelle Rempel Conservative Calgary Nose Hill, AB

Thank you.

If Canada at the federal level had a vigorous rollout plan for the deployment of rapid tests, would that change the modelling you presented today?

3:20 p.m.

Acting Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada

Dr. Guillaume Poliquin

We will return to you with the number of inputs that go into these models to be remitted.

3:20 p.m.

Conservative

Michelle Rempel Conservative Calgary Nose Hill, AB

Do you think it's concerning you can't answer that question at this hearing today?

3:20 p.m.

Acting Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada

Dr. Guillaume Poliquin

Mr. Chair, the models that are presented are a number of complex modelling exercises that involve a number of different inputs. It is difficult to—

3:20 p.m.

Conservative

Michelle Rempel Conservative Calgary Nose Hill, AB

What are those inputs?

3:20 p.m.

Acting Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada

Dr. Guillaume Poliquin

They include reproductive numbers and they include a number of trends, as well as the interplay of the rollout of vaccination and expected and diffuse transmission patterns, therefore it is difficult to tease apart individual assumptions at the moment.

3:20 p.m.

Conservative

Michelle Rempel Conservative Calgary Nose Hill, AB

Why is Canada's modelling for the spread of the variants so different from that of other countries? Why do we show such a greater trend, as opposed to models that have been recently released in, let's say, the EU or the U.S.?

3:20 p.m.

Acting Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada

Dr. Guillaume Poliquin

Mr. Chair, the models that are presented involve a number of different scenarios, including working for variants of concern in a range of potential increased transmissibility. The model that was presented today involved a 50% increase in transmissibility over the wild-type strain.

3:20 p.m.

Conservative

Michelle Rempel Conservative Calgary Nose Hill, AB

Did it assume the deployment of rapid tests?

3:20 p.m.

Acting Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada

Dr. Guillaume Poliquin

The interplay of testing with the number of cases is a different action.

3:20 p.m.

Conservative

Michelle Rempel Conservative Calgary Nose Hill, AB

So that wasn't included in today's modelling?

3:20 p.m.

Acting Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada

Dr. Guillaume Poliquin

We will return to you with the full set of assumptions modelled today.

3:20 p.m.

Conservative

Michelle Rempel Conservative Calgary Nose Hill, AB

Did the inclusion of unapproved vaccine candidates factor into your modelling today?

3:20 p.m.

Acting Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada

Dr. Guillaume Poliquin

Of unapproved vaccines?

3:20 p.m.

Conservative

Michelle Rempel Conservative Calgary Nose Hill, AB

Yes, like AstraZeneca or J&J, or were you just assuming we were proceeding with the existing schedules of Pfizer and Moderna?

3:20 p.m.

Acting Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada

Dr. Guillaume Poliquin

The interplay of the vaccines involves a number of different assumptions, and we will return to you with those.

3:20 p.m.

Conservative

Michelle Rempel Conservative Calgary Nose Hill, AB

By next week?

3:20 p.m.

Acting Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada

3:20 p.m.

Conservative

Michelle Rempel Conservative Calgary Nose Hill, AB

Thank you.

3:20 p.m.

Liberal

The Chair Liberal Ron McKinnon

We go now to Dr. Powlowski.

Dr. Powlowski, please go ahead for six minutes.